Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeuti BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE ...

It's been a mediocre week for Omnicell, Inc. (NASDAQ:OMCL) shareholders, with the stock dropping 11% to US$40.16 in the week since its latest annual results. Revenues were US$1.1b, approximately ...

CEO Randall Lipps highlighted that Omnicell exceeded bookings guidance for 2024, driven by strong connected devices demand. He emphasized the traction of the XT Amplify program and new customer ...

My name is Kathleen and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell Fourth Quarter and Full Year 2024 Financial Results Call.

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more. We sell different types of products and services to both investment ...

Omnicell (OMCL) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.33 per share a year ago. These figures ...

OMNICELL ($OMCL) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $0.60 per share, beating estimates of $0.59 by $0.01 ...

Full Year 2024 Non-GAAP EPS: $1.71, a decrease of $0.20 from 2023. Full Year 2024 Non-GAAP EBITDA: $136 million. Omnicell Inc (NASDAQ:OMCL) exceeded its bookings guidance for 2024, driven by strong ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the ...